Cellbri Cell & Gene Tech Expo August 2026: Cell Therapy

Traditional cell therapy manufacturing often forces developers into a difficult compromise: endure labor-intensive manual steps or forfeit process optimization to rigid, proprietary platforms. Open-architecture, closed automation offers a practical alternative by combining modular flexibility with end-to-end efficiency.

By decoupling critical unit operations from rigid workflows, manufacturers can modernize production while protecting biological performance. Flexible, configurable instrumentation allows teams to scale labor efficiency, streamline cleanroom footprint requirements, and maintain fine-grained control over process parameters. Real-world commercial deployments show that adapting open, automated systems directly reduces cost of goods, expands output capacity, and broadens global patient access—without forcing developers to re-validate established protocols. Discover how modernizing cell processing workflows can help reduce manufacturing costs and expand patient access.

About CellBri:

CellBri is a biotechnology solutions company dedicated to delivering accessible, flexible automation for the next generation of cell and gene therapies. Founded in 2020, our modular, GMP-ready platforms are designed to streamline manufacturing while preserving end-user control and configurability. Today, CellBri’s technologies have been adopted into over 100 cell therapy pipelines worldwide and used in 8 commercial cell therapies, underscoring our commitment to enabling scalable, high-quality cell processing through flexible automation.